Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + tislelizumab + oxaliplatin + S-1 + trastuzumab
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial People's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intraperitoneal, Intravenous, Oral
01
Overview
This combination therapy regimen, evaluated in the HISTORIA trial, is a conversion treatment for patients with gastric or esophagogastric junction cancer and peritoneal metastasis. The protocol involves Hyperthermic Intraperitoneal Chemotherapy (HIPEC) using paclitaxel to target peritoneal disease, followed by systemic therapy. The systemic component includes the PD-1 inhibitor tislelizumab, the SOX chemotherapy regimen (oxaliplatin and the oral fluoropyrimidine S-1), and the HER2-targeted monoclonal antibody trastuzumab for patients with HER2-positive tumors. This multimodal approach combines cytotoxic chemotherapy, immunotherapy, and targeted therapy to maximize tumor response and facilitate radical surgical resection.
- Other names
- HIPEC + PD-1 + SOXHIPEC + Tislelizumab + SOX + TrastuzumabHIPEC + PD-1 + SOX + Herceptin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + tislelizumab + oxaliplatin + S-1 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + tislelizumab + oxaliplatin + S-1 + trastuzumab.